Seaport Therapeutics Showcases Phase 1 Progress of SPT-300

Seaport Therapeutics Presents Latest Data from Phase 1 Study of SPT-300

BOSTON-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company, has announced notable developments regarding its Founded Entity, Seaport Therapeutics. The company recently presented additional data from its innovative SPT-300 study during the American College of Neuropsychopharmacology (ACNP) Annual Meeting. This meeting serves as a prestigious platform for experts in neuropsychopharmacology to share advancements and insights in their fields.

Understanding SPT-300

SPT-300 is an oral prodrug of allopregnanolone, an endogenous neurosteroid. This compound has shown potential as a rapid antidepressant with anxiolytic (anxiety-reducing) effects validated by third-party trials. During the recent Phase 1 study, which included healthy volunteers, researchers sought to evaluate the drug's safety, tolerability, pharmacokinetics, and its effect on GABA_A receptors, known for their role in reducing neuronal excitability throughout the nervous system.

Highlights from the Phase 1 Study

The Phase 1 trial encompassed 99 participants and involved several crucial evaluations: double-blind single ascending dose, multiple ascending dose, and open-label food effect assessments. These comprehensive analyses allowed the team to gather significant data regarding SPT-300's effects on oral bioavailability and overall safety. The results confirmed that SPT-300 was predominantly well-tolerated, with adverse events being mild to moderate, transient, and dose-dependent.

Among the notable adverse events reported, somnolence was the most common, illustrating that while SPT-300 has pharmacodynamic activity, monitoring is an essential component of its use. Importantly, the therapeutic levels achieved with SPT-300 were up to approximately nine times higher than those linked with the traditional allopregnanolone treatment, which has shown limited bioavailability.

Implications for the Future

The data presented emphasizes SPT-300's suitability for chronic dosing, particularly in a placebo-controlled Phase 2b study focused on major depressive disorder. The Phase 1 study revealed increased EEG beta frequency power and reduced saccadic eye velocity, showcasing the compound's potential efficacy. It was also observed that somnolence, the prominent side effect, peaked around 4 hours following dosing, lending insight into its pharmacodynamics and guiding future treatment protocols.

Expert Insights on SPT-300 Developments

Dr. Tony Loebel, Chief Medical Officer and President of Clinical Development at Seaport Therapeutics, expressed optimism regarding the findings. He remarked on the well-tolerated nature of SPT-300 and its rapid acting pharmacodynamic effects, highlighting the demand for innovative neuropsychiatric solutions. Dr. Loebel emphasized that the oral form of allopregnanolone can provide significant advantages for patients requiring ongoing management of depressive and anxious symptoms.

About Seaport Therapeutics

Seaport Therapeutics operates in a space that is crucial for advancing neuropsychiatric treatments to meet high unmet needs. The company is known for leveraging its proprietary Glyph technology platform, which enables oral bioavailability and minimizes side effects often associated with traditional delivery methods. By fostering a pipeline rich in potential first and best-in-class therapies, Seaport is poised to impact the treatment landscape for patients suffering from various neuropsychiatric conditions.

About PureTech Health

PureTech Health is dedicated to revolutionizing medicine to help those afflicted by severe diseases. Their robust research and development initiatives are supported by a widespread network of professionals across various sectors within science and healthcare. This synergy has led to the establishment of 29 therapeutic programs, three of which have received approval from the U.S. Food and Drug Administration. PureTech's commitment to innovative solutions continues to drive forward the clinical development of its therapeutics, either independently or through its Founded Entities.

Frequently Asked Questions

What is SPT-300?

SPT-300 is an oral prodrug of allopregnanolone, designed to function as a rapidly acting antidepressant with potential anxiolytic effects.

How did the Phase 1 study evaluate SPT-300?

The Phase 1 study assessed SPT-300's safety, tolerability, pharmacokinetics, and its engagement with GABA_A receptors in healthy volunteers.

What were the notable side effects observed in the study?

The primary side effect noted was somnolence, which was mild, transient, and dose-dependent in nature.

What are the next steps for SPT-300 development?

Following the positive Phase 1 data, a Phase 2b placebo-controlled study is planned to delve deeper into its efficacy for treating major depressive disorder.

What is the significance of PureTech Health’s role in this development?

PureTech Health provides essential support and infrastructure for Seaport Therapeutics, facilitating the development of new therapeutic candidates like SPT-300.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.